title: Dietary medium-chain triglyceride supplementation has no effect on apolipoprotein B-48 and apolipoprotein B-100 kinetics in insulin-resistant men.
abstract: BACKGROUND
  Medium-chain triglyceride (MCT) supplements are used by clinicians to treat patients with severe hypertriglyceridemia who are at risk of pancreatitis. However, the potential mechanisms underlying the effects of MCT on triglyceride-rich lipoprotein (TRL) metabolism have not yet been thoroughly examined in humans.
  
  
  OBJECTIVE
  This double-blind randomized crossover study compared the impact of 4 wk of supplementation with 20 g MCT oil/d or 20 g corn oil/d on the kinetics of apolipoprotein (apo) B-48-containing TRLs and apo B-100-containing very-low-density lipoprotein (VLDL), as well as on the expression of key intestinal genes involved in lipid metabolism in 28 obese, insulin-resistant men.
  
  
  METHODS
  The in vivo kinetics of TRL apo B-48 and VLDL apo B-100 were assessed by using a primed-constant infusion of l-[5,5,5-d3]leucine for 12 h in the fed state. Real-time polymerase chain reaction quantification was performed on duodenal biopsy samples taken at the end of each phase of supplementation.
  
  
  RESULTS
  Compared with corn oil, MCT supplements had no significant effect on plasma lipoprotein profile or TRL apo B-48 and VLDL apo B-100 kinetics. Positive correlations were observed between the intestinal expression of several key genes involved in lipoprotein metabolism in a subgroup of participants (n = 16) after MCT supplementation. However, there was no difference between MCT and the corn oil control supplement in the intestinal messenger RNA expression levels of these key genes.
  
  
  CONCLUSIONS
  These data indicate that short-term supplementation with MCT has a neutral effect on TRL apo B-48 and VLDL apo B-100 kinetics and on the intestinal expression of genes involved in lipid and fatty acid metabolism in men with insulin resistance. This trial was registered at www.clinicaltrials.gov as NCT01806142.
authors.affiliation: Institute of Nutrition and Functional Foods (AJT, BL, M-ÈL, M-CL, and PC), the Lipid Research Centre, Centre hospitalier de l'Université Laval (CHUL) Research Centre (AJT and PC), and the Department of Gastroenterology, CHUL (VL), Laval University, Quebec City, Canada.
authors.forename: André J
authors.initials: AJ
authors.lastname: Tremblay
authors.forename: Benoît
authors.initials: B
authors.lastname: Lamarche
authors.forename: Marie-Ève
authors.initials: MÈ
authors.lastname: Labonté
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Lépine
authors.forename: Valéry
authors.initials: V
authors.lastname: Lemelin
authors.forename: Patrick
authors.initials: P
authors.lastname: Couture
mesh_terms: D000328:Adult; D053299:Apolipoprotein B-100 / Q000097:blood*; D053283:Apolipoprotein B-48 / Q000097:blood*; D018592:Cross-Over Studies; D004032:Diet; D019587:Dietary Supplements; D004311:Double-Blind Method; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood / Q000150:complications / Q000188:drug therapy; D007333:Insulin Resistance; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000187:drug effects; D050356:Lipid Metabolism / Q000187:drug effects; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood; D010195:Pancreatitis / Q000097:blood / Q000209:etiology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D014280:Triglycerides / Q000008:administration & dosage* / Q000097:blood
chemical_list: D053299:Apolipoprotein B-100; D053283:Apolipoprotein B-48; D008079:Lipoproteins, VLDL; D012333:RNA, Messenger; D014280:Triglycerides